Evidence-based goals in LDL-C reduction
H Soran, R Dent, P Durrington - Clinical research in cardiology, 2017 - Springer
The evidence from trials of statin therapy suggests that benefits in cardiovascular disease
(CVD) event reduction are proportional to the magnitude of low-density lipoprotein …
(CVD) event reduction are proportional to the magnitude of low-density lipoprotein …
Lipids, lipid-lowering therapy, and neuropathy: a narrative review
ABSTRACT Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are the
mainstay of treatment for hypercholesterolemia as they effectively reduce LDL-C levels and …
mainstay of treatment for hypercholesterolemia as they effectively reduce LDL-C levels and …
Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: results from DYSIS II Europe
J Ferrieres, GM De Ferrari, MP Hermans… - European journal of …, 2018 - academic.oup.com
Background Patients with coronary heart disease (CHD) and survivors of acute coronary
syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low …
syndrome (ACS) are at very high risk for adverse cardiovascular events. Lowering low …
Efficacy and safety of PCSK9 monoclonal antibodies
Z Iqbal, S Dhage, JB Mohamad… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel
drugs that have been developed since the discovery of the PCSK9 protein in 2003. In …
drugs that have been developed since the discovery of the PCSK9 protein in 2003. In …
[PDF][PDF] Hypercholesterolaemia–practical information for non-specialists
Hypercholesterolaemia – practical information for non-specialists Page 1 Guidelines
Corresponding author: Dr Handrean Soran MSc, MD, FRCP Consultant Physician and …
Corresponding author: Dr Handrean Soran MSc, MD, FRCP Consultant Physician and …
Efficacy and safety of PCSK9 monoclonal antibodies in patients with Diabetes
Purpose Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs
that have proven efficacy in improving cardiovascular outcomes. Roles for the PCSK9 …
that have proven efficacy in improving cardiovascular outcomes. Roles for the PCSK9 …
Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance
Background and aims There is disquiet about statin effectiveness and side effects in both the
medical and lay media. Methods We searched the literature for reports on the incidence of …
medical and lay media. Methods We searched the literature for reports on the incidence of …
Optimising treatment of hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and …
Background and aims Guidelines for cholesterol-lowering medication either advocate fixed
dose statin treatment without low density lipoprotein (LDL) cholesterol targets or treatment …
dose statin treatment without low density lipoprotein (LDL) cholesterol targets or treatment …
Advances in the pharmacological management of hyperlipidemia through the use of combination therapies
AS Wierzbicki - Expert Opinion on Pharmacotherapy, 2024 - Taylor & Francis
Introduction Lipid-lowering therapies are well established for the treatment of cardiovascular
disease (CVD). Historically monotherapy studies have been performed, but the introduction …
disease (CVD). Historically monotherapy studies have been performed, but the introduction …
[HTML][HTML] Cardiovascular prevention: frontiers in lipid guidelines
EJ Kim, AS Wierzbicki - Clinical Medicine, 2020 - Elsevier
Cardiovascular disease (CVD) remains one of the principal causes of morbidity and
mortality in the world. International guidelines are being updated to take into account new …
mortality in the world. International guidelines are being updated to take into account new …